KFSHRC attracts international patients by offering specialized cardiology, oncology, neurosciences, organ transplant, and ...

Elevated levels of soluble and tumor-bound ULBP6 confirmed in squamous cell carcinomas and a subset of adenocarcinomas, offering potential indications to assess clinical activity ...

Between June 5 and December 12, 2023, ten adult patients with advanced ccRCC who received a median of four prior treatment lines (range: 2-7) were enrolled and received a median of three cycles (range ...

Overall, the Company believes that the results to date from the TAMARACK study indicate antitumor activity associated with vobra duo in mCRPC as demonstrated by the protocol-specified primary endpoint ...

Janssen-Cilag International NV, a Johnson & Johnson company, today announced additional results from the pivotal Phase 2b SunRISe-1 study, supporting the safety and efficacy profile of investigational ...

We remain confident in the proven profile of Cabometyx as a monotherapy and in combination with immunotherapy, across approved and potential future indications ...

By continuously refining its practices through real-time feedback and innovative solutions, KFSHRC remains a leader in ...

Cullinan and Taiho have a broad development program for zipalertinib through a suite of REZILIENT studies, including two ongoing pivotal studies in 1L and 2L+ ex20ins NSCLC as well as studies in other ...

Dr. Pardeep Nijhawan (“Dr. Nijhawan”) announces that as a result of grants of restricted share units (“RSUs”) of Edesa Biotech, Inc. (“Edesa”), when combined with a series of transactions (the ...

The presented posters “ Advancing a multi-dimension KRAS mutation-specific T cell receptor (TCR) library with a 3S TCR targeting the G12D mutation to address large global patient populations ” and “ ...

While the FDA will take into consideration the committee’s vote, the vote is not binding upon the agency. The FDA will make the final decision and has assigned a Prescription Drug User Fee Act (PDUFA) ...

OrigAMI-1 is the first study to show amivantamab plus chemotherapy may provide clinically meaningful benefits to patients with metastatic colorectal cancer who have not received any EGFR-targeted ...